A Webinar By Steve Loftus, Business Steering Group Leader for Microbial

The webinar delves into the use of inclusion bodies within biopharmaceutical production, which have gone from historically being considered undesirable byproducts of microbial expression systems to eventually gaining attention for their potential in producing a range of difficult to express proteins in E. coli systems.

The presentation aims to highlight the advantages of insoluble expression and address the challenges associated with purification. We also present and outline FUJIFILM Diosynth Biotechnologies’ approach to developing and scaling up these types of processes for a diverse range of biologics.

Key Learning Objectives:

  • Unraveling the friend aspect and overcoming the foe
  • Process Development strategies
  • Scale-up considerations and approaches

View the Webinar